Holen Sie sich die Stockscreener-App
6.92
0.14%
-0.010
Handel nachbörslich:
6.92
Fulcrum Therapeutics Inc Aktie (FULC) Neueste Nachrichten
Bank of America Corp DE Has $432,000 Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Research Analysts Issue Forecasts for FULC FY2026 Earnings - Defense World
Citadel Advisors LLC Makes New $69,000 Investment in Lisata Therapeutics, Inc. (NASDAQ:LSTA) - Defense World
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Acquired by Millennium Management LLC - Defense World
Comparing Fulcrum Therapeutics (NASDAQ:FULC) and Lakeshore Biopharma (NASDAQ:LSB) - Defense World
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Two Sigma Investments LP - Defense World
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FULC Stock News - GuruFocus
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - MarketScreener
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fulcrum Therapeutics Awards Major Stock Options Package: 70,000 Shares at $6.96 Exercise Price - Stock Titan
Fulcrum Therapeutics, Inc. (FULC): A Bull Case Theory - MSN
BNP Paribas Financial Markets Makes New Investment in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics (NASDAQ:FULC) shareholders are up 16% this past week, but still in the red over the last five years - simplywall.st
Fulcrum Therapeutics to Present at Upcoming Medical Meetings | FULC Stock News - GuruFocus
Fulcrum Therapeutics to Present at Upcoming Medical Meetings - Eagle-Tribune
New Oral Sickle Cell Drug Shows Promise: Fulcrum to Reveal Phase 1 Trial Results at Global Medical Conferences - Stock Titan
Fulcrum Therapeutics to Participate in the 46th Annual Goldman S - GuruFocus
Fulcrum Therapeutics (FULC) Target Price Raised Amid Key Data An - GuruFocus
FULC: Piper Sandler Raises Price Target for Fulcrum Therapeutics | FULC Stock News - GuruFocus
Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference | FULC Stock News - GuruFocus
Rare Disease Innovator Fulcrum Therapeutics Takes Stage at Elite Goldman Sachs Healthcare Conference - Stock Titan
Fulcrum gains as Leerink upgrades ahead of data for lead asset - MSN
Fulcrum Therapeutics (NASDAQ:FULC) Upgraded at Leerink Partners - Defense World
Leerink Partnrs Upgrades Fulcrum Therapeutics (NASDAQ:FULC) to Strong-Buy - Defense World
Leerink raises Fulcrum Therapeutics stock to Outperform By Investing.com - Investing.com Canada
Northern Trust Corp Buys 142,578 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics Shares Rise After Upgrade From Leerink - marketscreener.com
Fulcrum stock gains as Leerink upgrades (FULC:NASDAQ) - Seeking Alpha
Fulcrum Therapeutics (FULC) Receives Analyst Upgrade and Increas - GuruFocus
Leerink Partners Upgrades Fulcrum Therapeutics (FULC) - Nasdaq
Leerink Upgrades Fulcrum Therapeutics to Outperform From Market Perform, Adjusts Price Target to $12 From $4 - marketscreener.com
Fulcrum Therapeutics (FULC) Receives Analyst Upgrade on Positive Outlook | FULC Stock News - GuruFocus
Fulcrum Therapeutics at RBC Capital: Strategic Steps in Sickle Cell Treatment - Investing.com Canada
Cantor Fitzgerald Predicts FULC FY2025 Earnings - Defense World
Price T Rowe Associates Inc. MD Raises Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Upgraded by Cantor Fitzgerald - Defense World
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $6.67 Average Price Target from Analysts - Defense World
Cantor Fitzgerald Upgrades Fulcrum Therapeutics (FULC) - Nasdaq
Fulcrum Therapeutics Shares Rise After Cantor Fitzgerald Upgrade - marketscreener.com
Fulcrum Therapeutics (FULC) Upgraded to Overweight by Cantor Fit - GuruFocus
Cantor Fitzgerald Upgrades Fulcrum Therapeutics to Overweight From Neutral, Price Target is $10 - marketscreener.com
FULC Stock Upgraded to Overweight by Cantor Fitzgerald with $10 - GuruFocus
FULC Stock Upgraded to Overweight by Cantor Fitzgerald with $10 Target | FULC Stock News - GuruFocus
Fulcrum Therapeutics (FULC) Upgraded by Cantor Fitzgerald with P - GuruFocus
Fulcrum Therapeutics (FULC) Upgraded by Cantor Fitzgerald with Positive Outlook | FULC Stock News - GuruFocus
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Dimensional Fund Advisors LP - Defense World
Wells Fargo & Company MN Has $161,000 Stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics (FULC) to Release Quarterly Earnings on Monday - Defense World
0.68%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):